Amgen gets quick appeal in CareFirst’s US antitrust case over Enbrel
MLex Summary: Amgen's request to immediately appeal CareFirst’s US case accusing it of unlawfully delaying competition for its drug Enbrel has been granted by a Virginia federal judge. US District Judge...To view the full article, register now.
Already a subscriber? Click here to view full article